Compare UXIN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | REPL |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 756.6M | 692.8M |
| IPO Year | 2018 | 2018 |
| Metric | UXIN | REPL |
|---|---|---|
| Price | $3.53 | $6.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.13 |
| AVG Volume (30 Days) | 115.6K | ★ 1.2M |
| Earning Date | 03-13-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $237.18 | N/A |
| Revenue Next Year | $145.46 | N/A |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $2.68 |
| 52 Week High | $5.40 | $13.24 |
| Indicator | UXIN | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 50.10 | 41.92 |
| Support Level | $3.21 | $6.89 |
| Resistance Level | $3.83 | $10.54 |
| Average True Range (ATR) | 0.19 | 0.53 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 45.16 | 18.10 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.